A clinical stage company developing a sustained-release drug delivery platform with broad applications. Our first product, ST-01, has successfully completed its Phase II trial and is moving towards a Phase III trial. We have two other products in Phase II trials. ST-01 is an injected non-opioid pain medication designed to address large markets with high unmet needs. It has the potential to provide effective, long-lasting non-addictive pain management for up to four weeks from a single injection. ST-01’s Phase II trial in chronic pain was successful. We anticipate commencing its Phase III trial in 2026, subject to regulatory approval. ST-02, our second product, is a sustained release chemotherapy medication. We have initiated a Phase II study in an orphan indication, Upper Tract Urothelial Carcinoma (UTUC). Our third product, ST-04, has begun its Phase II trial. ST-04 is an ED medication being tested in men who are non-responsive to standard of care PDE-5 inhibitors.